A Randomized, Double-Blind, Placebo-Controlled Phase Ib/Ii Study Of Ralimetinib, A P38 Mapk Inhibitor, Plus Gemcitabine (G) And Carboplatin (C) Versus Gc For Women With Recurrent Platinum-Sensitive Ovarian Cancer.
JOURNAL OF CLINICAL ONCOLOGY（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要